- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07942090
Role of 68Ga-FAPI PET/CT in Patients in Whom 18F-FDG PET/CT Has Been Found to be Questionable or Inconclusive Due to Oncological Pathology (FAPI-MN-2020)
To evaluate the accuracy of [68Ga]Ga-FAPI PET/CT in detecting the presence of oncological disease in patients with inconclusive or equivocal findings after the standard clinical/diagnostic flow chart: [18F]F-FDG PET/CT imaging not able to solve the clinical doubt or equivocal/inconclusive for the evaluation of oncological disease.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Studied population Approximately 200 patients will be enrolled with inconclusive or equivocal findings after the standard clinical/diagnostic flow chart: [18F]F-FDG PET/CT imaging not able to solve the clinical doubt or equivocal/inconclusive for the evaluation of oncological disease.
Patients enrolled must satisfy all the inclusion criteria and must sign an informed consent. The informed consent will be signed by the patient in the nuclear medicine department before the performance of any experimental procedure.
Primary aim
Secondary aim
To evaluate the accuracy of [68Ga]Ga-FAPI PET/CT in detecting the presence of oncological disease in patients with inconclusive or equivocal findings after the standard clinical/diagnostic flow chart: [18F]F-FDG PET/CT imaging not able to solve the clinical doubt or equivocal/inconclusive for the evaluation of oncological disease.
To evaluate accuracy, sensitivity and specificity of [68Ga]Ga-FAPI PET/CT and [18F]F-FDG PET/CT (standard examination currently performed in several oncological settings) in detecting the presence of oncological disease in patients with inconclusive or equivocal findings after the standard clinical/diagnostic flow chart: [18F]F-FDG PET/CT imaging not able to solve the clinical doubt or equivocal/inconclusive for the evaluation of oncological disease.
Primary endpoint accuracy of [68Ga]Ga-FAPI PET/CT in detecting the presence of oncological disease in patients with inconclusive or equivocal findings after the standard clinical/diagnostic flow chart: [18F]F-FDG PET/CT imaging not able to solve the clinical doubt or equivocal/inconclusive for the evaluation of oncological disease.
Secondary enpoint accuracy, sensitivity and specificity of [68Ga]Ga-FAPI PET/CT and [18F]F-FDG PET/CT (standard examination currently performed in several oncological settings) in detecting the presence of oncological disease in patients with inconclusive or equivocal findings after the standard clinical/diagnostic flow chart: [18F]F-FDG PET/CT imaging not able to solve the clinical doubt or equivocal/inconclusive for the evaluation of oncological disease.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
Italy
-
Bologna, Italy, Itália, 40138
- IRCCS Azienda Ospedaliero Universitaria di Bologna
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
-
Inclusion criteria • Age ≥18 years old
- Both sexes
- Patients with oncological disease suspicion/ new diagnosis or with a previously treated tumour (with previous treatments performed at least 3 months before enrollment) and with an inconclusive or equivocal [18F]F-FDG PET/CT, especially cases of:
-
Suspect primary or secondary (lymph-nodes or distant metastases) lesions with absent/faint FDG uptake or low TBR;
-
And/or suspect primary or secondary (lymph-nodes or distant metastases) lesions in a site of phisiological FDG uptake (such as brain or liver) or in sites in which FDG has a low sensitivity (i.e. peritoneal carcinomatosis, esophageal-gastro-intestinal tract);
-
And/or low glucose metabolism tumour hystotypes (i.e. renal clear cell carcinoma, mucinous mammary tumours, well differentiated HCC);
-
And/or differential diagnosis between tumour and inflammation (i.e. determining lymph-nodes benign or malignant nature in head/neck cancers, differential diagnosis between inflammation or malignant tissue in sarcomas).
- Signed informed consent
Exclusion Criteria: Exclusion Criteria • Pregnancy. In order to rule out pregnancy a β-hCG blood test will be performed in women of childbearing age.
- Breastfeeding
- Patients in emergency situations or unfit to plead.
- History of allergic reactions or hypersensitivity to the active substance, to any of the excipients, or to any of the components of the radiolabeled radiopharmaceutical
- Contraindication to PET / CT examination for patients unable to perform PET due to weight, claustrophobia or the inability to remain still for the duration of the examination
- Participation in a clinical trial in which an investigational drug was administered within 30 days or 5 half-lives before the study drug
- Patients with impaired renal function;
- Patients with impaired liver function;
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Diagnóstico
- Alocação: Não randomizado
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
diagnostic performance
Prazo: 9 years
|
sensitivity, specificity, AUC, detection rate, accuracy, positive and negative predictive value compared to the reference standard. |
9 years
|
Colaboradores e Investigadores
Patrocinador
Publicações e links úteis
Publicações Gerais
- Giesel FL, Kratochwil C, Lindner T, Marschalek MM, Loktev A, Lehnert W, Debus J, Jager D, Flechsig P, Altmann A, Mier W, Haberkorn U. 68Ga-FAPI PET/CT: Biodistribution and Preliminary Dosimetry Estimate of 2 DOTA-Containing FAP-Targeting Agents in Patients with Various Cancers. J Nucl Med. 2019 Mar;60(3):386-392. doi: 10.2967/jnumed.118.215913. Epub 2018 Aug 2.
- Chen H, Pang Y, Wu J, Zhao L, Hao B, Wu J, Wei J, Wu S, Zhao L, Luo Z, Lin X, Xie C, Sun L, Lin Q, Wu H. Comparison of [68Ga]Ga-DOTA-FAPI-04 and [18F] FDG PET/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer. Eur J Nucl Med Mol Imaging. 2020 Jul;47(8):1820-1832. doi: 10.1007/s00259-020-04769-z. Epub 2020 Mar 28.
- Kratochwil C, Flechsig P, Lindner T, Abderrahim L, Altmann A, Mier W, Adeberg S, Rathke H, Rohrich M, Winter H, Plinkert PK, Marme F, Lang M, Kauczor HU, Jager D, Debus J, Haberkorn U, Giesel FL. 68Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer. J Nucl Med. 2019 Jun;60(6):801-805. doi: 10.2967/jnumed.119.227967. Epub 2019 Apr 6.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Doenças urogenitais
- Doenças Genitais
- Doenças do Sistema Endócrino
- Neoplasias urogenitais
- Neoplasias por local
- Neoplasias
- Doenças Urogenitais Femininas
- Doenças urogenitais femininas e complicações na gravidez
- Doenças Respiratórias
- Doenças Genitais Femininas
- Doenças pulmonares
- Neoplasias das Glândulas Endócrinas
- Neoplasias do Trato Respiratório
- Neoplasias Torácicas
- Doenças ovarianas
- Doenças anexiais
- Neoplasias Genitais Femininas
- Distúrbios Gonadais
- Doenças de pele
- Doenças da mama
- Doenças da Pele e do Tecido Conjuntivo
- Neoplasias Pulmonares
- Neoplasias ovarianas
- Neoplasias da Mama
- Neoplasias de Cabeça e Pescoço
- 68Ga-fapi
Outros números de identificação do estudo
- FAPI-MN-2020
- 2020-005549-17 (Número EudraCT)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .